MacroGenics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. 

CEO
Eric Risser
CEOEric Risser
Employees
293
Employees293
Headquarters
Rockville, Maryland
HeadquartersRockville, Maryland
Founded
2000
Founded2000
Employees
293
Employees293

MGNX Key Statistics

Market cap
142.05M
Market cap142.05M
Price-Earnings ratio
-2.64
Price-Earnings ratio-2.64
Dividend yield
—
Dividend yield—
Average volume
785.44K
Average volume785.44K
High today
$2.27
High today$2.27
Low today
$2.05
Low today$2.05
Open price
$2.26
Open price$2.26
Volume
997.66K
Volume997.66K
52 Week high
$5.08
52 Week high$5.08
52 Week low
$1.32
52 Week low$1.32

Stock Snapshot

MacroGenics(MGNX) stock is priced at $2.20, giving the company a market capitalization of 142.05M. It carries a P/E multiple of -2.64.

During the trading session on 2026-11-15, MacroGenics(MGNX) shares reached a daily high of $2.27 and a low of $2.05. At a current price of $2.20, the stock is +7.3% higher than the low and still -3.1% under the high.

Trading activity shows a volume of 997.66K, compared to an average daily volume of 785.44K.

Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $5.08 and a low of $1.32.

Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $5.08 and a low of $1.32.

MGNX News

TipRanks 2d
MacroGenics Updates Corporate Presentation With Clinical Program Details

The latest announcement is out from MacroGenics ( (MGNX) ). On November 13, 2026, MacroGenics made available an updated corporate presentation reflecting updat...

TipRanks 3d
MacroGenics reports Q3 EPS (32c), consensus (13c)

Reports Q3 revenue $18.67M, consensus $39.18M. The revenue decrease was primarily due to $50M in milestone revenue recognized in 2025 under the Provention asset...

Analyst ratings

50%

of 6 ratings
Buy
50%
Hold
50%
Sell
0%

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.